Bioventus Inc. (BVS)

NMS – Real Time Price. Currency in USD

10.14

-0.05 (-0.49%)

At close: May 12, 2026, 4:00 PM EDT

10.14

0.00 (0.00%)

After-hours: May 12, 2026, 4:10 PM EDT

08.05.2026

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

06.05.2026

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

06.05.2026

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.

06.05.2026

Bioventus Reports First Quarter Financial Results

DURHAM, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 28, 2026.

05.05.2026

Should Value Investors Buy Bioventus (BVS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

29.04.2026

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

28.04.2026

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market opens on Wednesday, May 6, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Videos

No Data

There is no data to display

Press releases

06.05.2026

Bioventus Reports First Quarter Financial Results

05.03.2026

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased 97% 2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026.

05.12.2025

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders.

04.11.2025

Bioventus Reports Third Quarter Financial Results

DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025.

Bioventus Inc. (BVS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bioventus Inc. (BVS)

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus Reports First Quarter Financial Results

Should Value Investors Buy Bioventus (BVS) Stock?

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Videos

No Data

Press releases

Bioventus Reports First Quarter Financial Results

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Bioventus Reports Third Quarter Financial Results

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus Reports First Quarter Financial Results

Should Value Investors Buy Bioventus (BVS) Stock?

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Videos

No Data

Press releases

Bioventus Reports First Quarter Financial Results

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Bioventus Reports Third Quarter Financial Results

Search stocks

Bioventus Inc. (BVS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bioventus Inc. (BVS)

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus Reports First Quarter Financial Results

Should Value Investors Buy Bioventus (BVS) Stock?

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Videos

No Data

Press releases

Bioventus Reports First Quarter Financial Results

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Bioventus Reports Third Quarter Financial Results

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventus Reports First Quarter Financial Results

Should Value Investors Buy Bioventus (BVS) Stock?

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Videos

No Data

Press releases

Bioventus Reports First Quarter Financial Results

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Bioventus Reports Third Quarter Financial Results